(Q38763747)

6 September 2017

title

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics (English)

1 reference

6 September 2017

Li Shen

1

1 reference

6 September 2017

Ashley Orillion

series ordinal

2

1 reference

6 September 2017

Roberto Pili

series ordinal

3

1 reference

6 September 2017

publication date

7 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

8

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

415-428

1 reference

Histone deacetylase inhibitors: molecular mechanisms of action

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Regulation of nuclear translocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The many faces of insulin-like peptide signalling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

B7 family checkpoint regulators in immune regulation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Clinical Toxicities of Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Early epigenetic events regulate the adaptive immune response gene CIITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors suppress natural killer cell cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone/protein deacetylases and T-cell immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Acetylation of RNA Processing Proteins and Cell Cycle Proteins in Mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Activation of terminal B cell differentiation by inhibition of histone deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Dendritic cell development requires histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors impair antibacterial defenses of macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI.15.118

21 January 2018

Identifiers

DOI

10.2217/EPI.15.118

1 reference

6 September 2017

1 reference